COVID-19 vaccine (NVXCoV2373) granted Fast Track Designation by U.S. FDA
NVX-CoV2373 is a vaccine candidate engineered from genetic sequence of SARS-CoV-2 and contains saponin-based Matrix-M™ adjuvant to enhance immune response and stimulate high levels of neutralising antibodies. Phase 3 clinical trial in US and Mexico to begin by the end of November
Source:
Biospace Inc.